Trial · NCT02434328
Adverse events376
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 376
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cataract - Fellow eye | Eye disorders | Brolucizumab 6mg | 7 | 370 | |
| other | Cataract - Fellow eye | Eye disorders | Aflibercept 2mg | 22 | 369 | |
| other | Cataract - Study eye | Eye disorders | Brolucizumab 6mg | 11 | 370 | |
| other | Cataract - Study eye | Eye disorders | Aflibercept 2mg | 43 | 369 | |
| other | Conjunctival haemorrhage - Study eye | Eye disorders | Brolucizumab 6mg | 17 | 370 | |
| other | Conjunctival haemorrhage - Study eye | Eye disorders | Aflibercept 2mg | 19 | 369 | |
| other | Eye pain - Study eye | Eye disorders | Brolucizumab 6mg | 13 | 370 | |
| other | Eye pain - Study eye | Eye disorders | Aflibercept 2mg | 19 | 369 | |
| other | Neovascular age-related macular degeneration - Fellow eye | Eye disorders | Brolucizumab 6mg | 31 | 370 | |
| other | Neovascular age-related macular degeneration - Fellow eye | Eye disorders | Aflibercept 2mg | 32 | 369 | |
| other | Visual acuity reduced - Study eye | Eye disorders | Brolucizumab 6mg | 31 | 370 | |
| other | Visual acuity reduced - Study eye | Eye disorders | Aflibercept 2mg | 25 | 369 | |
| other | Bronchitis | Infections and infestations | Brolucizumab 6mg | 22 | 370 | |
| other | Bronchitis | Infections and infestations | Aflibercept 2mg | 20 | 369 | |
| other | Influenza | Infections and infestations | Brolucizumab 6mg | 24 | 370 | |
| other | Influenza | Infections and infestations | Aflibercept 2mg | 27 | 369 | |
| other | Nasopharyngitis | Infections and infestations | Brolucizumab 6mg | 43 | 370 | |
| other | Nasopharyngitis | Infections and infestations | Aflibercept 2mg | 31 | 369 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Brolucizumab 6mg | 16 | 370 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Aflibercept 2mg | 28 | 369 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02434328/events